GO
Loading...

Enter multiple symbols separated by commas

Stocks Actavis Inc

More

  • Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • UPDATE 1-Actavis' superbug antibiotic gets U.S. approval Wednesday, 25 Feb 2015 | 7:50 PM ET

    Feb 25- The U.S. Food and Drug Administration on Wednesday approved the use of Actavis Plc's antibiotic, Avycaz, to battle drug-resistant bacteria known as superbugs. Although a number of companies including Roche Holdings AG, Tetraphase Pharmaceuticals Inc, Achaogen Inc and Cempra Inc, are developing drugs for a variety of superbugs, Gabelli& Co analyst Kevin...

  • TOKYO, Feb 20- Activist investor Daniel Loeb said Fanuc Corp's plan to boost investments was not enough to fix its "blatant capital inefficiency", stepping up calls for the Japanese industrial robot maker to reward shareholders through major buybacks. Loeb, whose hedge fund Third Point holds an undisclosed stake in Fanuc, told Reuters by email the plan to double...

  • NEW YORK, Feb 18- Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs. Actavis, which began as a New Jersey- based generics company called Watson, took its current...

  • UPDATE 2-Actavis beats profit estimates, raises forecast Wednesday, 18 Feb 2015 | 9:11 AM ET

    Feb 18- Actavis Plc posted a better-than-expected adjusted quarterly profit and raised its full-year earnings forecast, saying it expected strong sales of its new branded drugs. Actavis agreed to buy Allergan Inc last November for $66 billion, outbidding a hostile offer by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  • Actavis, which bought Botox-maker Allergan Inc in November, makes drugs from research in its own pipeline, and copy cat versions of other popular drugs. Sales of the Actavis's branded drugs nearly tripled to $1.83 billion in North America in the fourth quarter, accounting for 45 percent of total revenue. For the fourth quarter ended Dec. 31, Actavis's net loss...

  • *Deal builds on last year's purchase of Almirall drugs. LONDON, Feb 5- AstraZeneca has agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial $600 million as it seeks external deals to ensure growth. AstraZeneca will also pay another $100 million, after Actavis agreed to a number of changes to ongoing agreements...

  • LONDON, Feb 5- AstraZeneca said on Thursday it had agreed to buy Actavis' branded respiratory drug business in the United States and Canada for an initial payment of $600 million as it seeks external deals to ensure growth. The British group, which saw off a $118 billion bid by Pfizer last year, said its sales in the fourth quarter fell 2 percent to $6.68 billion,...

  • Last month's return on Treasuries was the biggest since a 3.54 percent jump in December 2008, according to an index compiled by Bank of America Merrill Lynch. "We are giving back some of the gains from the short-covering rally last week," said Suvrat Prakash, interest rate strategist at HSBC Securities USA in New York. Apple Inc. planned to raise $5 billion in the...

  • Early Movers: GPRO, MSFT, SHW, HOG, WMT & more Friday, 12 Dec 2014 | 8:04 AM ET

    Some of the names on the move ahead of the open.

  • Hedge funds playing buy-and-hold, and losing Monday, 24 Nov 2014 | 10:54 AM ET
    An Apple store in New York.

    Hedge funds aren't changing their stock holdings much despite poor performance compared with the broader stock market.

  • Ackman has the luck of a loser, to the tune of $2.2B Tuesday, 18 Nov 2014 | 7:02 AM ET
    Bill Ackman

    Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.

  • Mega-mergers are popular again on Wall Street Tuesday, 18 Nov 2014 | 6:47 AM ET

    Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.

  • Early movers: AAPL, AZN, SHPG, FB, MSFT, DB & more Tuesday, 23 Sep 2014 | 7:41 AM ET
    A trader works on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • Early movers: HSY, SHLD, BX, BA, LMNT, BABA & more Tuesday, 16 Sep 2014 | 7:35 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer: Get this company on your radar, now! Monday, 4 Aug 2014 | 6:33 PM ET

    Ahead of earnings, Jim Cramer thinks you should know about this stock and the potential it presents.

  • Cooperman: Buy these stocks now Wednesday, 16 Jul 2014 | 12:22 PM ET
    Omega Advisors CEO Leon G. Cooperman speaks at the CNBC Institutional Investor Delivering Alpha Conference in New York.

    Billionaire investor Leon Cooperman gave 12 stock recommendations at the Delivering Alpha conference Wednesday.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Early movers: NFLX, WYNN, APP & more Tuesday, 1 Jul 2014 | 7:56 AM ET

    Some of the names on the move ahead of the open.

  • Why rivals are jealous of Pfizer's AstraZeneca deal Thursday, 1 May 2014 | 7:15 AM ET
    U.S. drugmaker Pfizer proposed buying AstraZeneca for about 58.8 billion pounds ($98.7 billion) in what would rank as the industry's biggest-ever takeover, surpassing Pfizer's $64 billion purchase of Wyeth in 2009.

    As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.